These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18304655)

  • 1. Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles.
    Schneider T; Becker A; Ringe K; Reinhold A; Firsching R; Sabel BA
    J Neuroimmunol; 2008 Mar; 195(1-2):21-7. PubMed ID: 18304655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with TGF-beta antisense oligonucleotide-modified autologous tumor vaccine enhances the antitumor immunity of MBT-2 tumor-bearing mice through upregulation of MHC class I and Fas expressions.
    Tzai TS; Shiau AL; Liu LL; Wu CL
    Anticancer Res; 2000; 20(3A):1557-62. PubMed ID: 10928070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotide specific for transforming growth factor-beta 1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer.
    Tzai TS; Lin CI; Shiau AL; Wu CL
    Anticancer Res; 1998; 18(3A):1585-9. PubMed ID: 9673374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model.
    Dorigo O; Shawler DL; Royston I; Sobol RE; Berek JS; Fakhrai H
    Gynecol Oncol; 1998 Nov; 71(2):204-10. PubMed ID: 9826461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors.
    Liu Y; Wang Q; Kleinschmidt-DeMasters BK; Franzusoff A; Ng KY; Lillehei KO
    J Neurooncol; 2007 Jan; 81(2):149-62. PubMed ID: 16941073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats.
    Iwadate Y; Inoue M; Saegusa T; Tokusumi Y; Kinoh H; Hasegawa M; Tagawa M; Yamaura A; Shimada H
    Clin Cancer Res; 2005 May; 11(10):3821-7. PubMed ID: 15897582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra-arterial delivery of endostatin gene to brain tumors prolongs survival and alters tumor vessel ultrastructure.
    Barnett FH; Scharer-Schuksz M; Wood M; Yu X; Wagner TE; Friedlander M
    Gene Ther; 2004 Aug; 11(16):1283-9. PubMed ID: 15164099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma.
    Fakhrai H; Mantil JC; Liu L; Nicholson GL; Murphy-Satter CS; Ruppert J; Shawler DL
    Cancer Gene Ther; 2006 Dec; 13(12):1052-60. PubMed ID: 16826191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravascular site-specific delivery of a therapeutic antisense for the inhibition of restenosis.
    Yang J; Zeng Y; Li Y; Song C; Zhu W; Guan H; Li X
    Eur J Pharm Sci; 2008 Dec; 35(5):427-34. PubMed ID: 18848882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
    Lin CY; Chuang TF; Liao KW; Huang YJ; Pai CC; Chu RM
    Cancer Lett; 2008 Dec; 272(2):285-95. PubMed ID: 18760876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect.
    Weyermann J; Lochmann D; Georgens C; Zimmer A
    Eur J Pharm Biopharm; 2005 Apr; 59(3):431-8. PubMed ID: 15760723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor.
    Wang Y; Saad M; Pakunlu RI; Khandare JJ; Garbuzenko OB; Vetcher AA; Soldatenkov VA; Pozharov VP; Minko T
    Clin Cancer Res; 2008 Jun; 14(11):3607-16. PubMed ID: 18519795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.
    Gordon EM; Levy JP; Reed RA; Petchpud WN; Liu L; Wendler CB; Hall FL
    Int J Oncol; 2008 Oct; 33(4):665-75. PubMed ID: 18813779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.
    Fakhrai H; Dorigo O; Shawler DL; Lin H; Mercola D; Black KL; Royston I; Sobol RE
    Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2909-14. PubMed ID: 8610141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical application of antisense oligonucleotide-loaded chitosan nanoparticles to rats.
    Ozbaş-Turan S; Akbuğa J; Sezer AD
    Oligonucleotides; 2010 Jun; 20(3):147-53. PubMed ID: 20180684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration.
    Lu W; Sun Q; Wan J; She Z; Jiang XG
    Cancer Res; 2006 Dec; 66(24):11878-87. PubMed ID: 17178885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of immunotherapy of IL-6 and IL-15 plasmids on transmissible venereal tumor in beagles.
    Chou PC; Chuang TF; Jan TR; Gion HC; Huang YC; Lei HJ; Chen WY; Chu RM
    Vet Immunol Immunopathol; 2009 Jul; 130(1-2):25-34. PubMed ID: 19200609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense TGF-beta2 immunotherapy for hepatocellular carcinoma: treatment in a rat tumor model.
    Maggard M; Meng L; Ke B; Allen R; Devgan L; Imagawa DK
    Ann Surg Oncol; 2001; 8(1):32-7. PubMed ID: 11206222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on polymethacrylate nanoparticles as delivery system of antisense oligodeoxynucleotides].
    Wang WX; Chen HL; Liang WQ
    Yao Xue Xue Bao; 2003 Apr; 38(4):298-301. PubMed ID: 12889133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.
    Kang N; Tang L; Li X; Wu D; Li W; Chen X; Cui L; Ba D; He W
    Immunol Lett; 2009 Aug; 125(2):105-13. PubMed ID: 19539651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.